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Interestingly, we created our model of
ischemic cardiomyopathy by placing an
ameroid constrictor on the branch of the
circumflex artery in 12 adult sheep.
In our experiment, 4 weeks after con-
striction, we randomly assigned 3 groups
(4 animals per group) to transpericardial
injection (3 sites per animal): sham treat-
ment (saline solution with denatured cells),
control (no injections), and endothelial cell
fibrin meshwork groups (autologous ma-
ture endothelial cells, 5  105 per injec-
tion site harvested from jugular veins).
Eight weeks after transepicardial treat-
ment, animals were assessed for myocar-
dial function (by means of echocardiog-
raphy), myocardial blood flow (MBF),
and capillary area (by means of histolo-
gy).
We demonstrated improved capillary
density and MBF in keeping with their
speculation that, “A coronary ligation
model of myocardial infarction, in which
a more extensive peri-infarct border
zone could harbor viable but hypoper-
fused cardiomyocytes and endothelial
cells, might result in greater angiogene-
sis.”
One month after constriction, MBF in
the ischemic myocardium decreased to
70% of baseline value (P  .001). Two
months after reoperation and the beginning
of treatment, animals were killed, and MBF
was found to have decreased to 28% versus
baseline values in the control and saline
solution groups (P  .001). MBF in the
endothelial cell group significantly in-
creased to 108%.
In normal nonischemic myocardium in
all 3 groups, there were 205.54  12.31
capillaries/mm2. Three months after con-
striction (and 2 months after reoperation
and beginning of treatment) in the control
and saline solution groups, there was a
decrease up to 51% in capillaries per
square millimeter (P  .001 vs baseline).
However, although this decreased signifi-
cantly in the control and saline solution
groups versus baseline values, in the endo-
thelial cell group this increased to 146%
(P  .001). Hence all of our results con-
firmed those in the report of Kim and as-
sociates.1
However, they also concluded that “in-
creasing blood flow by endothelial cell
transplantation in this model did not im-
prove contractility or prevent ventricular
dilatation,” and “we plan to perform autol-
ogous endothelial cell transplantation in
our clinically relevant porcine model of
occlusion of the left anterior descending
coronary artery. We anticipate that angio-
genesis may improve regional and global
function.”
In our investigation, 4 weeks after con-
striction, left ventricular ejection fraction
(LVEF) decreased to 75% (P .001). Two
months later, LVEF decreased to 57% in
the control and saline groups (P  .001 vs
4 weeks and baseline). In the endothelial
cell group LVEF increased to 89% of base-
line values but continued to be less than
baseline value (P  .05). However, LVEF
in this group was significantly better than
in the control and saline solution groups
(P  .001).
On the basis of our data, we think that
use of endothelial cell transplantation
within a 3-dimensional matrix system can
be used to induce angiogenesis in patients
who cannot be adequately revascularized
by using standard techniques. Exploring
autologous mature endothelial cell trans-
plantation might become a useful alterna-
tive to gene and protein therapy. We recently
completed studies involving a large number
of animals; these results are pending.
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Reply to the Editor:
Chekanov and Kipshidze performed a se-
ries of experiments that appear to confirm
our findings that endothelial cell transplan-
tation improved perfusion after myocardial
injury. Recently, a variety of techniques
have been used to induce angiogenesis to
treat patients who are not candidates for
conventional methods of revascularization.
Cell transplantation has the advantage of
inducing angiogenesis by a variety of
mechanisms because the technique is not
limited to the release of a single protein.
Chekanov and Kipshidze used an endo-
thelial cell fibrin meshwork applied to the
epicardial surface of an ischemic region.
They found that this technique induced an-
giogenesis. The mode of delivery and the
number of cells engrafted might critically
affect the benefits achieved with cell trans-
plantation. The optimal conditions have not
been well defined. In addition, the cell type
that induces the most beneficial response
has not been adequately established. Endo-
thelial cells induce an extensive capillary
network, but they might not induce the
formation of sufficient conduit vessels.
Further research into this important area
might establish which cell type, which cell
number, and which mode of delivery are
optimal to induce angiogenesis.
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Missing data from mesothelioma
study
To the Editor:
The phase II trial of surgery and radiation
of malignant mesothelioma by Rusch and
colleagues1 is an important addition to the
literature, documenting contemporary ef-
forts to control and eventually cure this so
far incurable malignant process. The 8%
mortality after extrapleural pneumonec-
tomy reflects the tremendous strides in sur-
gical technics effected in recent decades.
The rigorous staging confirms a major at-
tempt to bring better science to this capri-
cious disease.
Nevertheless, Rusch and colleagues1
have excluded a host of important informa-
tion from their publication. I hope that they
will be able to strengthen the report by
rectifying some of these omissions:
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1. To understand the real world from
which their patients were selected,
we need to know how many patients
were refused entry into their study.
2. The benefits of combined resection
and radiation therapy might be put
into better perspective if we could
see the survival data and curves on
the patients refused entry into the
study. All hospital tumor boards cer-
tified by the American Cancer Soci-
ety will have this information.
3. Because early studies by Devalle
and coworkers2 indicated a late sur-
gical mortality of 11% beyond the
usual 30-day perioperative period, it
is important to learn whether such
events still occurred in the 1990s.
Similarly, early reports noted by
Ruffie and colleagues3 indicated
10% late suicides after surgery. A
statement regarding the occurrence
or nonoccurrence of suicidal deaths
during long-term follow-up is im-
portant in assessing the quality of
life and the suffering of the patients.
4. What were the lengths of the hospi-
tal stays of the included and the ex-
cluded surgical groups? How many
days of hospitalization were required
in long-term follow-up for the com-
plications of radiation therapy and
surgery? These data are important in
assessing the patients’ quality of life
as well as the cost of care.
5. How many of the patients had large
recurrent or persistent pleural effu-
sions? Several investigators have
suggested a survival advantage for
this group relative to those with a
soft-tissue mass.
6. It is interesting that 69% of this se-
lected group of surgical patients had
such high staging (III and IV). By
comparison, Sugarbaker and associ-
ates4 found 136 of 183 (74%) to
have stage I and II disease in a series
that had excluded 2 to 3 patients for
every patient accepted. Does this dif-
ference indicate that Sugarbaker and
associates4 had a more effective
technique to screen out patients with
stage III and IV disease for surgical
resection? It is disappointing that so
few patients with stage I and II dis-
ease were found in the study of
Rusch and colleagues.1 Perhaps rig-
orous intraoperative staging up-
grades preoperative stage to the ex-
tent that few patients with stage I
and II disease remain, even with
prompt evaluation after the onset of
symptoms. Presumably nonsurgical
disease would be falsely staged
lower because of the absence of me-
diastinal sampling, laparoscopy, and
so on, making comparison of surgi-
cal and nonsurgical groups more dif-
ficult.
7. The median survival was stated to be
17 months in this study, but that
number excluded the 7 deaths and
the 21 patients whose disease could
not be completely resected. Obvi-
ously, we need to know the median
survival of all patients operated on,
including perioperative deaths, if we
are to provide honest informed con-
sent with surgical referrals.
8. Rigorous statistical assessment of
surgical trials becomes even more
important in light of a recent consec-
utive, unselected series of 26 pa-
tients with malignant mesothelioma
with pleural effusion and treated by
medical thoracoscopic talc pleurode-
sis as the primary modality of care.
They had a median survival of 19.4
months and have a mean survival
that is now reaching 22.8 months.5-7
Although Rusch7 has previously in-
dicated the difficulties of doing ran-
domized controlled studies in this
disease, such studies may be neces-
sary to separate theoretic from the
real benefits of surgery.
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Early bypass occlusion in patients
with the St Jude Medical Symmetry
connector
To the Editor:
In recent years, off-pump coronary artery
bypass grafting has gained increasing ac-
ceptance because of the reduction of pos-
sible negative effects of extracorporeal cir-
culation. This technique was shown to be
beneficial, especially in elderly patients.1
However, the manipulation of a possibly
diseased ascending aorta in elderly patients
might increase the risk for neurologic com-
plications.2
In May 2000, St Jude Medical, Inc
(Minneapolis, Minn) introduced an anasto-
motic device (Symmetry Aortic Connector
System) to facilitate the proximal vein–
aorta anastomosis without side clamping
the aorta. Since June 2001, we have used
the Symmetry mechanical anastomotic de-
vice preferably in off-pump coronary artery
bypass grafting procedures, especially
when transesophageal echocardiography
revealed a calcified ascending aorta.3 Be-
tween June 2001 and April 2002, we have
deployed the device in 51 male and 10
female patients (mean age, 68.6  8.6
years). A total of 77 Symmetry connectors
were used (1.3 per patient). Loading of the
connector was simple, and time for anasto-
mosis was less than 15 seconds. After de-
ployment, the free graft flow was assessed
by removing the bulldog clamp from the
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